The current invention relates to stents and methods for cannulating a vessel.
An intravenous cannula provides access to a vein and may allow blood to be drawn and fluids to be administered into a patient. In the case of hemodialysis, cannulation provides access to a fistula with quickened blood flow that may provide for effective dialysis. In dialysis treatment, needles, catheters, or other cannulas may be inserted into the blood vessels near a fistula to draw blood from the circulatory system, pass it through a dialysis machine, and return it to the body. However, cannulation can be difficult due to challenges in locating vessel sites, difficulty reaching vessels for vascular access due to an underlying layer of adipose tissue, collapse of a blood vessel being punctured, and complications from cannulation that may include hematoma, infiltration, thrombosis, and embolism. It would therefore be useful to find improved ways to access the vasculature for cannulation, and ways to modify blood flow to allow for alternative access sites, such as to improve access to blood vessels near a fistula.
Described here are devices, systems, and methods for improving retrograde blood flow through peripheral vasculature and to aid in cannulation. The devices, systems, and methods described herein may be used to hold open venous valves to allow bi-directional flow of blood through a vein. In some variations, a stent may be deployed in a blood vessel to hold open a valve to increase retrograde blood flow, aid in locating the blood vessel, and structurally support the blood vessel during cannulation. In some variations, a fistula may be formed to arterialize a vein and increase retrograde blood flow through the vein. In some variations, the methods described herein comprise methods for cannulating a first vessel comprising advancing a stent into the first vessel comprising one or more valves. The stent may be deployed over one or more valves to hold open the one or more valves. A needle may be advanced through a wall of the first vessel. In some variations, the needle may also be advanced through an aperture defined in a wall of the stent. In other variations, the needle may be advanced through the wall of the first vessel at a location distal to the stent. In some variations, stent location may be detected non-invasively. In some of these variations, the needle may be positioned over the first vessel using the detected stent location. In other variations, the stent comprises first struts and second struts having different thicknesses. In some variations, the first vessel may be a cephalic vein. In other variations, the first vessel may be a basilic vein.
In some variations, a first catheter may be advanced into an artery adjacent to a vein. The first catheter may comprise a fistula-forming element, and a fistula may be formed between the artery and the vein using the fistula-forming element. The stent may be deployed distal to the fistula. The artery may be an ulnar artery and the vein may be an ulnar vein. A second catheter may be advanced into the vein. In some instances, the first catheter and the second catheter may be aligned. One or more stents may be loaded into a third catheter. The one or more stents may be sequentially deployed from the third catheter into the first vessel by advancing a push wire through the third catheter.
Also described here are systems for forming a fistula and improving retrograde blood flow through peripheral vasculature. In general, the systems described herein may include a catheter system comprising a stent comprising one or more apertures defined in a wall of the stent. The stent may be configured to hold open one or more venous valves and receive a needle through one or more apertures. A first catheter may comprise a fistula-forming element. In some variations, the stent may comprise first struts and second struts having different thicknesses. The system may further comprise a plurality of the stents and a second catheter comprising a push wire configured to deploy one or more stents sequentially from a distal end of the second catheter. The fistula-forming element may be an electrode. The needle may be a cannula. The system may further comprise a stent detector coupled to a needle injector coupled to the needle.
Generally described here are devices, systems, and methods for providing a stent in peripheral vasculature to permit retrograde blood flow, to support cannulation of a vein, and/or to percutaneously create one or more arteriovenous fistulae for increasing venous blood flow, such as for increasing retrograde blood flow through a forearm vein to be cannulated. Accordingly, it may be helpful to briefly describe the anatomy of the vasculature of the arm.
Also shown in
Generally, the systems, devices, and methods described herein may be used to hold open venous valves to permit retrograde blood flow in a blood vessel, to assist in locating a vascular access site, and/or to provide structural support to a blood vessel to aid in cannulation (e.g., needle puncture into the blood vessel). In some variations, one or more of these uses may be in conjunction with formation of a fistula between two blood vessels (e.g., an arteriovenous fistula between an artery and a vein). In some variations, a delivery system may be utilized to deploy one or more structures (e.g., stents) in a target blood vessel where the deployed structures may increase blood flow and aid in cannulation.
Generally, the systems and methods may be used to hold open unidirectional venous valves in a vein to allow arterialized blood flow (e.g., from an arteriovenous fistula between an artery and a vein) to travel distally through the vein and provide a preferred conduit for retrograde blood flow. Generally, to create a retrograde blood flow path through a vein, a stent may be advanced in a minimally invasive manner through the vasculature to a peripheral vein (e.g., a vein segment in the forearm). The stent may be placed in the peripheral vein to hold open one or more venous valves to permit retrograde blood flow. For example, the sidewalls of the stent may push one or more unidirectional valves against the inner circumference of the vein so as to hold open the valves in the vein without damaging them. Opening the valves using a stent may allow blood to flow retrograde through the vein without removing the venous valves, as would be required in a valvulotomy procedure. For example, opening the valves using a stent may allow arterialized blood flow from a fistula to flow retrograde through the vein without removing the venous valves. As the venous valves in the rest of the peripheral vasculature retain their function and inhibit retrograde flow, the portion of the vein having the stent provides a preferred retrograde blood flow pathway. The devices and systems described herein offer a reversible approach to rendering valves incompetent having improved procedural speed relative to a valvulotome that cuts the leaflets of the valves. In some instances, a single stent may be placed in a blood vessel. In other instances, a system comprising multiple stents may be deployed in one or more blood vessels. For example, in some instances, a stent may be placed in each of two veins (e.g., a cephalic vein and a basilic vein). In other instances, a stent may be placed in a vein and an accessory vein. It should be appreciated that each stent may or may not have the same configuration of elements, and that some stents may be different from and/or complementary to other stents.
Also generally described are systems comprising one or more stents to aid in cannulating a blood vessel by reducing damage and/or preventing collapse of the blood vessel being punctured. The stent may add radial strength and stiffness to the blood vessel in which it is disposed. These stents may be the same or different stents as those allowing retrograde venous blood flow. The one or more stents generally comprise a plurality of struts and may vary in length, diameter, thickness, geometric patterns, compressibility, and flexibility based on a target vessel, function, and delivery process. The stent may comprise a cannulation region having one or more apertures defined in a wall of the stent configured to receive a needle such as for cannulation.
Generally, the devices, systems and methods described herein may be used to cannulate a vein, such as a forearm vein. Generally, a stent may be advanced in a minimally invasive manner through the vasculature and placed in the vein. The stent may add to the strength and stiffness of the vein segment in which the stent is disposed, such as when being punctured by a needle. In some instances, the vein may be palpated and/or visualized to locate one or more of the stent and vein for cannulation. In other instances, the system may comprise a stent detector to non-invasively detect the stent disposed in the vein. For example, the stent detector may generate a signal when the presence of the stent is detected through the skin of the patient and output the signal to an operator. In some of these instances, a stent may define a cannulation region through which a needle may be advanced. Once a vein is located, an insertion point may be selected for a cannula such as a needle. The needle may be advanced through the skin and a vessel wall of the vein and an aperture defined in a wall (e.g., sidewall) of the stent. By advancing the needle through the vessel wall and stent having enhanced strength and stiffness, complications from cannulation such as infiltration, hematoma, and vein wall collapse may be reduced.
Generally, the systems described herein may comprise a stent detector and cannulator. These devices and systems may detect and locate the blood vessel for cannulation in cases where visualization and palpation are insufficient. In some variations, the stent detector may comprise a metal detector configured to detect a metal stent disposed in a vein. In some variations, the stent detector may comprise an output device to indicate to an operator the detected location of the stent under the skin. The cannulator (e.g., needle injector) may be coupled to a needle that may be advanced through skin and into a wall of a blood vessel and an aperture defined in a wall of the stent. In some instances, the system may output an audio tone when the system is located over the stent in the blood vessel.
Generally, one or more stents may be advanced in a minimally invasive manner through the vasculature and placed in the vein using a stent delivery system. These devices and systems offer a minimally invasive approach that may improve procedural speed by permitting deployment of one or more stents using a single catheter and deployment to smaller diameter blood vessels. Generally, to deliver and deploy one or more stents, one or more catheters may be advanced in a minimally invasive fashion through the vasculature to a target location. In some instances, a single catheter may be advanced to a target site in a blood vessel to deploy one or more stents. In other instances, a system comprising multiple catheters may be used to deliver and deploy one or more stents to target sites in respective blood vessels. For example, in some instances a catheter may be placed in each of the two blood vessels (e.g., different veins). One or both of the catheters may comprise a push wire (e.g., guidewire, stylet, push rod). The push wire may be configured to slide within the catheter to advance one or more stents out of a lumen of the catheter for deployment of a stent. For example, one or more stents may be loaded into a lumen of the catheter distal to the push wire. The stent may be configured to self-deploy to a predetermined shape when advanced out of the catheter and into a target blood vessel by the push wire. For example, a distal tip of the push wire may push a proximal end of the stent through a catheter lumen and out the distal end of the catheter. In these instances, it should be appreciated that each catheter may or may not have the same configuration of elements, and that some catheters may be different from and/or complementary to other catheters.
Generally, the systems and methods may be used to form and access a fistula in peripheral vasculature, such as in a forearm. These devices and systems offer a minimally invasive approach that may improve procedural speed. Generally, to form one or more fistulas between two blood vessels, one or more catheters may be advanced in a minimally invasive fashion through the vasculature to a target location. In some instances, a single catheter may be placed in a blood vessel to form a fistula with an adjoining blood vessel. In other instances, a system comprising multiple catheters may be used to form one or more fistulas. For example, in some instances a catheter may be placed in each of the two blood vessels (e.g., an artery and a vein). One or both of the catheters may comprise a fistula-forming element. The fistula-forming element(s) may comprise an electrode that is used to form the fistula such as through tissue ablation. The catheter may further comprise one or more alignment portions including magnets that help align one catheter relative to another catheter in related blood vessels and/or bring the catheters (and blood vessels) in closer approximation. In these instances, it should be appreciated that each catheter may or may not have the same configuration of elements, and that some catheters may be different from and/or complementary to other catheters.
I. Systems
The systems described here may comprise one or more stents to hold open one or more valves of a venous blood vessel, provide structural support to a vein in which it is disposed, and/or aid in access for cannulation. Generally, the stents may comprise a plurality of struts forming a cylindrical configuration. The stent may be placed in a blood vessel to hold the valves in an open configuration that allows bi-directional blood flow, and in particular, retrograde blood flow through a vein. Accordingly, it may be desirable that the stent have sufficient radial strength to hold open the valves, but be of minimal thickness and surface area (e.g., diaphanous) to limit platelet activation and stenosis. The radial strength, thickness, and surface area of the stents described herein may be significantly less than that of vascular stents for maintaining the patency of blood vessels. In some variations, a stent may hold one or more valves open, allow at least one of blood flow from a fistula and a needle to pass through an aperture defined in a sidewall of the stent, and provide structural support to the fistula.
A. Stent
Another variation is illustrated in
In some variations, the stents may be configured with dimensions to hold open venous valves and/or support the vessel during cannulation. In some variations, the stent may have an outer diameter between about 1 mm and about 20 mm. For example, the stent may have an outer diameter of about 5.0 mm. In some variations, the stent may have a strut width and thickness between about 0.05 mm and about 0.5 mm. In some variations, the stent may have side aperture openings disposed in a plane parallel to a longitudinal axis of the strut (e.g., the apertures being substantially orthogonal to the longitudinal axis of the strut) having a length between about 1 mm and about 15 mm and a width between about 1 mm and about 15 mm. For example, the stent may have an outer diameter of about 5.0 mm, a strut width of about 0.05 mm, a strut thickness of about 0.05 mm, and one or more diamond shaped apertures about 5 mm in width and about 10 mm in length.
In some variations, an axial portion of the stent may comprise a plurality of struts. For example, an axial portion of the stent may comprise a minimum of four struts to provide a predetermined minimum strut-to-leaflet ratio to achieve adequate valve leaflet opening when deployed in a vein. In some instances, the strut width and mesh density of the stent may be minimized so as to achieve a minimum stent area-to-intimal area ratio. In some variations, the strut surface area-to-vessel wall surface area ratio may be between about 0.02 and about 0.08. In some instances, this ratio may be between about 0.03 and 0.04. The stent may comprise any suitable configuration, such as a cylindrical configuration (e.g., tube) and/or helical spiral configuration. In some variations, the stent may have a length between about 5.0 cm and about 60 cm. For example, the stent may have a length of about 15.0 cm. The stent may be configured to fit within a lumen of a target blood vessel and press against the leaflets of a valve, such that they are moved into and held in an open configuration until the stent is removed.
The stent may be made of any suitable material, for example, one or more metals or polymers (e.g., stainless steel 316L, tantalum, nitinol, platinum iridium, niobium alloy, cobalt alloy, etc.). The stent may optionally be bioresorbable (e.g., made of poly-L lactic acid (PLLA) and may absorb over a time period of six months to three years) and may optionally comprise a drug eluting coating configured to prevent stenosis and/or thrombosis). The stent may be formed by any suitable manufacturing process, for example, laser cutting, photochemical etching, braiding, knitting, vapor deposition, water jet, etc. In some variations, the stent may comprise one or more coverings and/or visualization markers to aid in locating and positioning the stent within a vessel. For example, the stent may comprise a radiopaque marker and/or coating made of one or more of gold, platinum, tantalum, etc. that may be indirectly visualized.
In some variations, the stent may comprise multiple portions, each portion corresponding to a specific material, shape, and/or coating. For example, the stent may comprise a proximal portion comprising a coating for inducing thrombosis, a distal portion configured to prevent platelet aggregation and maximize fluid flow through the vessel, and an intermediate portion comprising a radiopaque marker surrounding an aperture and configured to permit visualization to aid in locating a blood vessel for cannulation. Of course, the stent may comprise any suitable number of portions (e.g., two, three, or four portions) and the length of each portion may be the same or different from the other portions. The stent may comprise any suitable length, and the length of the stent may vary depending on the type of procedure being performed.
In some variations, one or more portions of the stent may comprise a visual detection portion for indirectly visualizing the location and/or orientation of a stent with respect to a catheter system, target blood vessel, and/or external elements such as a cannulator. The visual detection portion may be visualized using a technique such as fluoroscopy during stent deployment and/or needle puncture of the blood vessel. In some instances, one or more characteristics of the stent such as echogenicity, radiopacity, surface area, surface area, permittivity, conductivity, permeability, and the like may be selected to enhance detection by, for example, fluoroscopy and/or a stent detector described herein. Fluoroscopy is a technique for real-time X-ray imaging where, generally, an X-ray beam is emitted from a fluoroscope through an area of interest in a body. Objects to be visualized (e.g., stents) may be imaged using an image intensifier. A user viewing the real-time images shown by the image intensifier may then determine the location and orientation of the one or more stents and use it to guide stent deployment and/or needle insertion.
Generally, a visual detection portion may be configured such that an aperture defined in a wall of the stent is discernable in a two-dimensional fluoroscopic image and/or detectable by a stent detector. In some variations, the portions of the stent configured for non-invasive detection may be used to guide positioning of a needle to be inserted through an aperture of the stent and the vessel wall. For example, one or more detection portions of the stent may surround an aperture of the stent and/or be provided at a predetermined location corresponding to the aperture. In some instances, the detection portions of the stent may comprise a set of patterns that may be visualized under fluoroscopy. For example, the visual detection portion may comprise an ellipsoid or polygon that may be fluoroscopically imaged. The shape of the visual detection portion may vary on a fluoroscopic image based on an orientation of the stent relative to the image intensifier. For example, a circular visual detection portion surrounding an aperture of the stent that appears as an ellipsoid on a fluoroscopic image may indicate that the aperture is non-perpendicular with respect to the image intensifier. Accordingly, the visual detection portion may be used to guide placement of a stent in a target blood vessel and/or cannula insertion through an aperture of the stent.
B. Stent Detector
The systems described here may comprise one or more of a stent detector configured to locate a stent disposed in a vessel and a cannulator (e.g., needle injector) configured to advance a needle through a wall of the blood vessel and the stent.
The output device (320) may receive the stent signal and use it to generate a signal to indicate that the stent has been located within a predetermined volume of space (e.g., the stent is directly beneath the location of the stent detector (300)). The output device (320) may output one or more signals to indicate a location of the stent relative to the stent detector (300). For example, the output device (320) may generate one or more audible tones and/or beeps to indicate proximity to a stent. In some variations, a set of colored lights may be output by the output device (320) to visually indicate a distance between the stent detector (300) and the stent. In some instances, the color, pattern, intensity, and number of lights may correspond to different ranges of distances between the stent detector (300) and the stent.
The output device (320) may comprise one or more of a display device, audio device, and haptic device. In some variations, the display device may be configured to display a graphical user interface (GUI). A display device may permit an operator to view patient data, sensor data, system data, alarms, and/or warnings. In some variations, an output device may comprise a display device including at least one of a light emitting diode (LED), liquid crystal display (LCD), electroluminescent display (ELD), plasma display panel (PDP), thin film transistor (TFT), organic light emitting diodes (OLED), and the like. An audio device may audibly output patient data, sensor data, system data, alarms, and/or warnings. For example, the audio device may output an audible warning when an operator actuates the stent detector (300) to inject the needle (340) when a stent is not detected within a predetermined range by the stent detector (300). In some variations, an audio device may comprise at least one of a speaker, piezoelectric audio device, magnetostrictive speaker, and/or digital speaker. A haptic device may provide additional sensory output (e.g., force feedback) to the operator. For example, a haptic device may generate a tactile response (e.g., vibration) to provide an alarm and/or warning. For example, haptic feedback may notify that operation of the cannulator is inhibited to prevent potential harm to the patient when a stent is not detected within a predetermined range. In some variations, the stent detector (300) may comprise a wired and/or wireless transmitter configured to transmit a stent signal to another device such as an external computing device including a desktop computer, server, database, and the like.
In some variations, a needle (340) may be advanced through the skin when the stent detector (300) locates the stent. The cannulator (330) may comprise a lumen to guide the needle (340). The needle (340) may be may be manually advanced from the cannulator (330) and/or actuated by the cannulator (330). The lumen may be configured to hold a needle (340) of any suitable size for cannulation, such as between about 12 gauge and about 20 gauge. The cannulator (330) may be configured to actuate when the stent is detected within a predetermined range to ensure that a needle (340) will advance through an aperture of the stent. Operation of the cannulator (330) may be inhibited and a notification output when the operator attempts to actuate the cannulator (330) when the stent is detected outside a predetermined range.
The stent detector (300) may comprise one or more processors and one or more machine-readable memories in communication with the one or more processors. The processor may incorporate data received from memory, sensor data, and operator input to control the stent detector (300). For example, the processor and memory may receive the stent signal from the sensor and determine a distance of the sensor to a stent. In some instance, the processor may compare the stent signal to a look-up-table. The processor may then select one or more notification methods based on the determined distance and user settings. The memory may further store instructions to cause the processor to execute modules, processes and/or functions associated with the stent detector (300). The processor and memory may be implemented consistent with numerous general purpose or special purpose computing systems or configurations. Various exemplary computing systems, environments, and/or configurations that may be suitable for use with the systems and devices disclosed herein may include, but are not limited to software or other components within or embodied on computing devices such as routing/connectivity components, multiprocessor systems, microprocessor-based systems, distributed computing networks, personal computing devices, network appliances, portable (e.g., hand-held) or laptop devices.
The processor may be any suitable processing device configured to run and/or execute a set of instructions or code and may include one or more data processors, image processors, graphics processing units, physics processing units, digital signal processors, and/or central processing units. The processor may be, for example, a general purpose processor, Field Programmable Gate Array (FPGA), an Application Specific Integrated Circuit (ASIC), and/or the like. The processor may be configured to run and/or execute application processes and/or other modules, processes and/or functions associated with the system and/or a network associated therewith. The underlying device technologies may be provided in a variety of component types such as metal-oxide semiconductor field-effect transistor (MOSFET) technologies like complementary metal-oxide semiconductor (CMOS), bipolar technologies like emitter-coupled logic (ECL), polymer technologies (e.g., silicon-conjugated polymer and metal-conjugated polymer-metal structures), mixed analog and digital, and/or the like.
In some variations, the memory may include a database and may be, for example, a random access memory (RAM), a memory buffer, a hard drive, an erasable programmable read-only memory (EPROM), an electrically erasable read-only memory (EEPROM), a read-only memory (ROM), Flash memory, and the like. As used herein, database refers to a data storage resource. The memory may store instructions to cause the processor to execute modules, processes and/or functions associated with the control system, such as stent detection, notification, calibration, cannulation, and/or device settings. In some variations, storage may be network-based and accessible for one or more authorized users. Network-based storage may be referred to as remote data storage or cloud data storage. Some variations described herein relate to a computer storage product with a non-transitory computer-readable medium (also may be referred to as a non-transitory processor-readable medium) having instructions or computer code thereon for performing various computer-implemented operations. The computer-readable medium (or processor-readable medium) is non-transitory in the sense that it does not include transitory propagating signals per se (e.g., a propagating electromagnetic wave carrying information on a transmission medium such as space or a cable). The media and computer code (also may be referred to as code or algorithm) may be those designed and constructed for the specific purpose or purposes. Examples of non-transitory computer-readable media include, but are not limited to, magnetic storage media such as hard disks, floppy disks, and magnetic tape; optical storage media such as Compact Disc/Digital Video Discs (CD/DVDs); Compact Disc-Read Only Memories (CD-ROMs); holographic devices; magneto-optical storage media such as optical disks; solid state storage devices such as a solid state drive (SSD) and a solid state hybrid drive (SSHD); carrier wave signal processing modules; and hardware devices that are specially configured to store and execute program code, such as Application-Specific Integrated Circuits (ASICs), Programmable Logic Devices (PLDs), Read-Only Memory (ROM), and Random-Access Memory (RAM) devices. Other variations described herein relate to a computer program product, which may include, for example, the instructions and/or computer code disclosed herein.
The systems, devices, and/or methods described herein may be performed by software (executed on hardware), hardware, or a combination thereof. Hardware modules may include, for example, a general-purpose processor (or microprocessor or microcontroller), a field programmable gate array (FPGA), and/or an application specific integrated circuit (ASIC). Software modules (executed on hardware) may be expressed in a variety of software languages (e.g., computer code), including C, C++, Java®, Python, Ruby, Visual Basic®, and/or other object-oriented, procedural, or other programming language and development tools. Examples of computer code include, but are not limited to, micro-code or micro-instructions, machine instructions, such as produced by a compiler, code used to produce a web service, and files containing higher-level instructions that are executed by a computer using an interpreter. Additional examples of computer code include, but are not limited to, control signals, encrypted code, and compressed code.
C. Stent Delivery System
Generally, one or more stents may be advanced in a minimally invasive manner through the vasculature and placed in the vein using a stent delivery system. Generally, to deliver and deploy one or more stents, one or more catheters may be advanced in a minimally invasive fashion through the vasculature to a target location. In some instances, a single catheter may be advanced to a target site in a blood vessel to deploy one or more stents. In other instances, a system comprising multiple catheters may be used to deliver and deploy one or more stents to different target sites in respective blood vessels. For example, in some instances a catheter may be placed in each of the two blood vessels (e.g., different veins). The catheter may comprise a push wire configured to advance within the catheter to push one or more stents out of a lumen of the catheter for deployment of a stent. For example, one or more stents may be pre-loaded into a lumen of the catheter distal to the push wire prior to introduction through vasculature. The push wire may be, for example, a guidewire, a stylet, a push rod, and the like. The push wire may be advanced within the catheter such that a distal end of the push wire pushes one or more stents out of the catheter and into a target blood vessel. The stent may be configured to self-deploy to a predetermined shape when advanced out of the catheter and into a target blood vessel by the push wire. In these instances, it should be appreciated that each catheter may or may not have the same configuration of elements, and that some catheters may be different from and/or complementary to other catheters. These devices and systems offer a minimally invasive approach that may improve procedural speed by permitting deployment of a plurality of struts using a single catheter and provide greater flexibility to allow stent delivery and deployment using smaller diameter blood vessels.
In some variations, the one or more stents that may be loaded within a lumen of the catheter may have the stent dimensions described herein. In some instances, the stents may be configured to be compressible and biased to transition from a compressed configuration to an expanded configuration (e.g., self-expand). In some variations, the diaphanous nature of the stent allows radial compression to a diameter of about 0.035 inches or less, thereby allowing loading of the stent into a 4 Fr catheter or smaller. For example, the stent may be configured in a compressed configuration when loaded into a catheter and biased to self-expand to an expanded configuration when deployed from the catheter and into a target blood vessel having a larger diameter lumen than the catheter. The catheters may have any suitable diameter for intravascular use, such as, for example, about 4 French or less. Any suitable catheter or catheters may be used with the systems described herein to deploy the stents using the methods described herein. A push wire of the catheter may have a diameter of up to an inner diameter of the catheter. The push wire may have any suitable configuration (e.g., diameter) for pushing one or more loaded stents out of a distal end of the catheter. The stents may have the same or different dimensions and characteristics.
D. Fistula Formation System
Also described here are systems for forming a fistula and improving retrograde blood flow through peripheral vasculature. Generally, the systems described here may comprise one or more catheters configured to be used to form a fistula in addition to a stent.
In some variations, the first catheter (401) may comprise a housing (413), which may help protect other components of the first catheter (401) during fistula formation. For example, when the fistula-forming element (409) comprises an electrode configured to ablate tissue, the housing (413) may comprise one or more insulating materials which may shield or otherwise protect one or more components of the first catheter (401) from heat that may be generated by the electrode during use.
As shown in
Certain exemplary devices and systems that may be used in the methods described herein are described in more detail in U.S. patent application Ser. No. 13/298,169, filed on Nov. 16, 2011, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” and U.S. patent application Ser. No. 15/406,755, filed on Jan. 15, 2017, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” the contents of each of which was previously hereby incorporated by reference in its entirety.
II. Methods
Described here are methods for aiding cannulation, improving retrograde blood flow, and delivering a stent to a vessel using the systems and devices described herein. Generally, the stents described herein may be used to aid in cannulation by assisting in locating the blood vessel and/or by structurally supporting the blood vessel during cannulation. For example, the stents may reduce damage and/or prevent collapse of a blood vessel being punctured during cannulation. Additionally or alternatively, the stents described herein may be used to increase retrograde blood flow through a vein by being deployed into a vein segment to hold open one or more venous valves to permit retrograde blood flow. In some of these variations, a stent may be deployed in conjunction with formation of an arteriovenous fistula to provide arterialized blood flow in a vein and/or aid cannulation of the fistula.
Generally, the stents described herein may be deployed by self-expansion or balloon expansion. For instance, a self-expanding stent in a compressed configuration may be constrained by a stent delivery system (e.g., a system comprising a conduit configured to hold the self-expanding stent in a compressed configuration) as it is advanced through vasculature in a minimally-invasive manner. Upon delivery to a target vessel by the stent delivery system, the self-expanding stent may transition from the compressed configuration to an expanded configuration. The stent delivery system may be withdrawn from the target vessel and the stent may remain within the target vessel. Similarly, a balloon expandable stent in a compressed configuration may be coupled to a stent delivery system comprising a deflated balloon as it is advanced through vasculature in a minimally-invasive manner. At a deployment location, the balloon of the stent delivery system may be inflated to expandably deform the stent to an expanded configuration. After the balloon is deflated, and the stent delivery system withdrawn, the stent may remain in the expanded configuration within the target vessel.
In some variations, blood flow in a vessel may be improved using the catheters, stents, and corresponding methods described in U.S. patent application Ser. No. 15/406,755, filed on Jan. 15, 2017, and titled “DEVICES AND METHODS FOR FORMING A FISTULA” and claiming the benefit of U.S. Provisional Application Ser. No. 62/399,471, filed on Sep. 25, 2016, and U.S. Provisional Application Ser. No. 62/279,603, filed on Jan. 15, 2016, the contents of each of which was previously hereby incorporated by reference in its entirety.
A. Cannulation
In some variations of the methods described here, the stents described herein may be used to aid in cannulation, such as by assisting in locating the blood vessel, and/or by structurally supporting the blood vessel during cannulation.
A stent may additionally or alternatively assist in location of the vessel by allowing other forms of detection. For example, a stent detector may be used to locate the stent and therefore locate the blood vessel in which the stent is disposed. In some variations, a sensor of a stent detector may comprise a metal detector configured to detect a metal content of a stent disposed in a blood vessel. For example, the stent detector may be swept over a patient's skin. This may be useful where visualization and palpation of a vein is difficult due to a thick layer of adipose tissue. An example is shown in
As shown in
A stent may additionally or alternatively assist in cannulation by structurally supporting the blood vessel during cannulation. For example, in some cases, cannulation of an arterialized vein may collapse the vein due to insufficient blood pressure. However, a stent disposed in a vein segment may increase the strength and stiffness of a portion of the vein to withstand cannulation without vein collapse and/or back-walling of the needle. Furthermore, cannulation of a vein may in some cases cause infiltration of the vein where blood leaks out of the vein and causes swelling in the perivascular space (e.g., hematoma). Infiltration may compress the vessel and cause an undesirable thrombosis. A stent disposed in the blood vessel may increase the radial strength of the vessel to reduce the compressive forces of cannulation and infiltration from closing the blood vessel shut.
B. Retrograde Flow
The methods described herein may also increase retrograde blood flow through a vein. Generally, the methods may comprise advancing one or more stents into peripheral vasculature. The stent may be deployed into a vein segment to hold open one or more valves. The stent may provide force on the venous valves to hold the leaflets of the valves in an open configuration. As such, the stent may hold one or more venous valves to frustrate the valves without cutting them. Furthermore, deployment of the stent may be faster and simpler than use of a valvulotome. For instance, deployment of the stent in a vessel may be performed without visualization (e.g., contrast injection) due to the symmetric and repeating configuration of the stent. Moreover, the sidewalls of the stent may additively increase the radial strength of the vein vessel walls, as described in more detail herein.
As mentioned above, use of a stent in venous tissue to frustrate one or more venous valves may be performed in fewer steps than a valvulotomy. A valvulotomy procedure to increase retrograde blood flow through a vein may require a user to visualize and locate a valve (e.g., using contrast), unsheathe the valvulotome, cut the leaflets with the valvulotome, resheath the valvulotome, and repeat the process for each valve to be cut. This may be a time consuming process, as the location, size, and spacing of valves in peripheral vasculature varies per individual. By contrast, a venous stent having a length sufficient to cover a desired vein segment may be located and deployed once to hold a plurality of valves in an open configuration irrespective of the location, size, and spacing of the valves. Put another way, a venous stent may in some instances prevent valve function over a desired vein segment in fewer steps and less time than a valvulotome. In addition, use of a venous stent to frustrate valves may be reversible (i.e., the stent may be removed from the vein to regain valve function), in contrast to a valvulotomy.
A length of a stent may be varied based on a desired length of retrograde blood flow in the vessel. For example, a longer stent disposed in a vein segment will cover and render incompetent a greater number of venous valves and thus allow for distal blood flow along a greater length of the vein. It may be desirable for the distal portion of the stent to have a minimal thickness and surface area necessary to hold open the venous valves.
In some variations, a stent may also increase retrograde blood flow through a vein by forming a proximal thrombus. For example, a stent may be configured to form a thrombus after being delivered to a vessel. Blood flow through the fistula may be thus be diverted distally to flow retrograde through the vein at a predetermined rate (e.g., over a week). A proximal portion of a stent may comprise, for example, copper to induce a thrombus over time. In other variations, the proximal portion of the stent may be electroplated, comprise a coating for inducing thrombosis, and/or be made of a thrombogenic fiber. Alternatively, the proximal portion of the stent may comprise a semi-permeable or impermeable membrane (e.g., cap, plug) to immediately reduce and/or eliminate proximal venous blood flow back to the heart. A distal portion of the stent may be configured to permit unobstructed blood flow through a lumen of the vein (e.g., by frustrating the venous valves). The distal portion may in some variations be configured to prevent platelet aggregation and maximize retrograde blood flow through the vein.
C. In Conjunction with a Fistula
The systems and methods described here may be used in some variations for cannulation of a fistula, such as for dialysis access. In some variations, the methods may comprise deploying a stent in conjunction with formation of an arteriovenous fistula to ease cannulation of the fistula, and/or to allow for additional cannulation sites. The fistula may in some variations be a surgically formed fistula. In other variations, the fistula may be formed by a minimally invasive procedure. For example, the fistula may be formed endovascularly using a catheter system as described herein.
More particularly, in some variations a fistula may be formed using a minimally invasive procedure by accessing a first blood vessel with a first catheter, and advancing the first catheter to a target location within a first blood vessel. A second blood vessel may be accessed with a second catheter, and the second catheter may be advanced to a target location within the second vessel. After the vessels are brought toward each other and aligned, one or more fistula-forming elements may be activated to bore through, perforate, or otherwise create a passageway between the two blood vessels such that blood may flow directly between the two adjoining blood vessels.
In some variations of methods in which a fistula is formed using a catheter system, the methods described herein may comprise aligning the first and second catheters. This may axially and/or rotationally align the catheters. For example, the catheters may be oriented such that a fistula-forming element of at least one of the first or second catheter is positioned to form a fistula in a certain location. In variations where both the first and second catheters comprise fistula-forming elements (e.g., an active electrode and a ground electrode, or each an active electrode), the catheters may be oriented to align these fistula-forming elements. The catheters may be aligned in any suitable manner. The first and second catheters may comprise any alignment element or combination of alignment elements. In some variations, each of the first and second catheters may comprise one or more magnetic alignment elements, which may generate an attractive force between the first and second catheters. This may pull the catheters toward each other and/or help to rotationally align them. Once the catheter or catheters are in position, one or more fistula-forming elements may be used to create a fistula between the two blood vessels, as described in more detail in U.S. patent application Ser. No. 13/298,169, filed on Nov. 16, 2011, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” and U.S. patent application Ser. No. 15/406,755, filed on Jan. 15, 2017, and titled “DEVICES AND METHODS FOR FORMING A FISTULA,” each of which was previously incorporated by reference in its entirety.
The methods involving stents described herein may allow for easier cannulation of a fistula, for example to allow for dialysis access, by assisting with locating the access site and/or by structurally supporting the blood vessel during cannulation, as described in more detail herein. Furthermore, the methods involving stents described herein may allow for additional cannulation sites by allowing for retrograde flow. For example, a venous stent may allow for cannulation in the forearm region of a patient. This may be desirable because a vessel for vascular access in hemodialysis is ideally located about 5 mm or less from the skin of the patient. However, some vessels, particularly in the upper arm, may be too deep below the skin for palpation and/or visualization due to an underlying layer of adipose tissue.
In some variations, the methods described herein may comprise forming a fistula and deploying a stent in vein, such as a cephalic vein and/or basilic vein. Arterialized blood flow may flow distally from the fistula and through the stent until meeting one or more accessory branches, at which point a portion of the retrograde blood may flow proximally through the one more accessory branches proximally towards the heart. Thus, the stent may define or expand a cannulation region (e.g., vein segment) having arterialized retrograde blood flow. In one particular variation, a stent as described herein may be deployed in the cephalic vein to frustrate the venous valves and allow for retrograde flow from a fistula distally. The stent may be placed distal to or through the region of the elbow crease and the forearm until the cephalic vein meets the accessory cephalic vein. This may allow cannulation of the cephalic vein in the forearm region. In this example, blood flow may return proximally via the accessory cephalic vein. The stent may additionally assist with cannulation in the forearm region by assisting with locating the vessel and structurally supporting the vein, as described herein.
Additionally or alternatively, a portion of a stent located in a vein proximally to a fistula may be used to form a thrombosis to drive arterial blood flow distally through the vein. In some of these variations, a portion of the stent may cover the fistula, and blood flow through the fistula may travel through the sidewall of the stent. The stent may form a thrombus as described in more detail herein. For example, a proximal portion of the stent may comprise copper to induce thrombus over time (e.g., a week). In other variations, the proximal portion of the stent may be electroplated, comprise a coating for inducing thrombosis, and/or be made of a thrombogenic fiber. Alternatively, the proximal portion of the stent may comprise a semi-permeable or impermeable membrane (e.g., cap, plug) to immediately reduce and/or eliminate proximal venous blood flow back to the heart. An intermediate portion of the stent, disposed between a proximal portion and a distal portion, may be disposed over a fistula and may be porous to permit blood flow from the fistula to flow into the vein. A distal portion of the stent may be configured to permit unobstructed blood flow through a lumen of the vein (e.g., by frustrating the venous valves).
D. Stent Delivery
The methods described herein may also deliver one or more of the stents described herein into a target vessel. Generally, the methods may comprise advancing and deploying one or more stents into peripheral vasculature using a single catheter. The use of the devices and systems described herein may be performed in fewer steps than using conventional stent delivery systems. Typical stent delivery systems include a catheter provided individually per stent. For example, a single stent is typically affixed to an end of a catheter and covered by an outer sleeve during advancement through vasculature. Once the stent is advanced to a desired location, the outer sleeve may be retracted so as to allow the stent to expand (e.g., using self-expansion and/or balloon expansion) and deploy into a target blood vessel. These systems using a catheter and sleeve are typically 6 French and greater in diameter. Accordingly, deployment of a plurality of stents may be a time consuming process that requires a set of corresponding delivery systems. By contrast, the stent delivery methods and systems described herein provide an easily operated and adaptable catheter that may be configured to deploy a plurality of stents sequentially without advancing and withdrawing individual catheters. Put another way, one or more stents may in some instances be deployed into one or more target blood vessel segments in fewer steps and less time than conventional stent delivery systems. The stents may have different configurations and be loaded sequentially together in the catheter. The stents may be configured with different dimensions, characteristics, and functions. For example, stents configured for vessel support may differ in one or more of materials, compressibility, detection, diameter, strut thickness, etc., from stents configured for vessel visualization. In addition, the stent delivery catheters described herein may have a compact configuration that allows advancement and deployment of stents in small diameter vessels.
In some variations, one or more stents may be deployed using a minimally invasive procedure by accessing a blood vessel with a catheter, and advancing the catheter to a target location within the blood vessel.
Once a distal end of the catheter (710) is positioned at a predetermined deployment location, the push wire (740) may be advanced within the catheter (710) to push the one or more stents (730) out of the distal end of the catheter (710) and into the target blood vessel.
In some variations, the stent (730) disposed in the catheter (710) is in a compressed configuration and transitions to an expanded configuration upon advancement out of the catheter (710) and into the target blood vessel. For example, the stent (730) may self-expand as the stent (730) is advanced into the target blood vessel having a larger diameter lumen than that of the catheter (710). In other variations, a balloon may be used to transition the stent into an expanded configuration through balloon inflation.
In variations in which a plurality of stents (730) are to be deployed, the stents (730) may be deployed in a sequential manner by advancement of the push wire (740) and/or retraction of the catheter (710). As one non-limiting example, a first stent may be deployed in a first blood vessel (e.g., vein) portion by advancing the push wire (740) to push the first stent out of the catheter (710) while the catheter (710) remains fixed relative to the first blood vessel. The first stent may self-expand (e.g., bias to form the expanded configuration) once disposed in the first blood vessel. The catheter (710) may be advanced through vasculature to another predetermined location and then used to deploy a second stent in a second vein portion by further advancing the push wire (740) to push the second stent out of the catheter (710). A third stent may be deployed in the second vein portion by retracting the catheter (710) relative to the second vein portion while maintaining the push wire (740) in position. The second and third stents may self-expand once disposed in the target blood vessel.
Although the foregoing variations have, for the purposes of clarity and understanding, been described in some detail by of illustration and example, it will be apparent that certain changes and modifications may be practiced, and are intended to fall within the scope of the appended claims. Additionally, it should be understood that the components and characteristics of the devices described herein may be used in any combination. The description of certain elements or characteristics with respect to a specific figure are not intended to be limiting or nor should they be interpreted to suggest that the element cannot be used in combination with any of the other described elements.
This application claims priority to U.S. Provisional Application Ser. No. 62/399,465, filed on Sep. 25, 2016, and titled “VASCULAR STENT DEVICES AND METHODS,” the content of which is incorporated by reference in its entirety.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2017/042937 | 7/19/2017 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2018/057095 | 3/29/2018 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 3649850 | Davis | Mar 1972 | A |
| 3827436 | Stumpf et al. | Aug 1974 | A |
| 4416664 | Womack | Nov 1983 | A |
| 4802475 | Weshahy | Feb 1989 | A |
| 5313943 | Houser et al. | May 1994 | A |
| 5697909 | Eggers et al. | Dec 1997 | A |
| 5800487 | Mikus et al. | Sep 1998 | A |
| 5830222 | Makower | Nov 1998 | A |
| 5830224 | Cohn et al. | Nov 1998 | A |
| 5895404 | Ruiz | Apr 1999 | A |
| 5971979 | Joye et al. | Oct 1999 | A |
| 6004330 | Middleman et al. | Dec 1999 | A |
| 6032677 | Blechman et al. | Mar 2000 | A |
| 6039730 | Rabin et al. | Mar 2000 | A |
| 6068638 | Makower | May 2000 | A |
| 6099542 | Cohn et al. | Aug 2000 | A |
| 6159225 | Makower | Dec 2000 | A |
| 6190353 | Makower et al. | Feb 2001 | B1 |
| 6197025 | Grossi et al. | Mar 2001 | B1 |
| 6217575 | DeVore et al. | Apr 2001 | B1 |
| 6231587 | Makower | May 2001 | B1 |
| 6256525 | Yang et al. | Jul 2001 | B1 |
| 6283988 | Laufer et al. | Sep 2001 | B1 |
| 6287306 | Kroll et al. | Sep 2001 | B1 |
| 6302875 | Makower | Oct 2001 | B1 |
| 6327505 | Medhkour et al. | Dec 2001 | B1 |
| 6347247 | Dev et al. | Feb 2002 | B1 |
| 6355029 | Joye et al. | Mar 2002 | B1 |
| 6357447 | Swanson et al. | Mar 2002 | B1 |
| 6379353 | Nichols | Apr 2002 | B1 |
| 6383180 | Lalonde et al. | May 2002 | B1 |
| 6400976 | Champeau | Jun 2002 | B1 |
| 6428534 | Joye et al. | Aug 2002 | B1 |
| 6461356 | Patterson | Oct 2002 | B1 |
| 6464665 | Heuser | Oct 2002 | B1 |
| 6464723 | Callol | Oct 2002 | B1 |
| 6468268 | Abboud et al. | Oct 2002 | B1 |
| 6475214 | Moaddeb | Nov 2002 | B1 |
| 6475226 | Belef et al. | Nov 2002 | B1 |
| 6527724 | Fenici | Mar 2003 | B1 |
| 6527769 | Langberg et al. | Mar 2003 | B2 |
| 6542766 | Hall et al. | Apr 2003 | B2 |
| 6544230 | Flaherty et al. | Apr 2003 | B1 |
| 6569158 | Abboud et al. | May 2003 | B1 |
| 6569162 | He | May 2003 | B2 |
| 6579311 | Makower | Jun 2003 | B1 |
| 6585650 | Solem | Jul 2003 | B1 |
| 6592577 | Abboud et al. | Jul 2003 | B2 |
| 6635053 | Lalonde et al. | Oct 2003 | B1 |
| 6655386 | Makower et al. | Dec 2003 | B1 |
| 6656173 | Palermo | Dec 2003 | B1 |
| 6663625 | Ormsby et al. | Dec 2003 | B1 |
| 6669709 | Cohn et al. | Dec 2003 | B1 |
| 6673085 | Berg | Jan 2004 | B1 |
| 6676657 | Wood | Jan 2004 | B2 |
| 6682525 | Lalonde et al. | Jan 2004 | B2 |
| 6695878 | McGuckin et al. | Feb 2004 | B2 |
| 6709444 | Makower | Mar 2004 | B1 |
| 6719756 | Muntermann | Apr 2004 | B1 |
| 6726697 | Nicholas et al. | Apr 2004 | B2 |
| 6733494 | Abboud et al. | May 2004 | B2 |
| 6736808 | Motamedi et al. | May 2004 | B1 |
| 6761708 | Chiu et al. | Jul 2004 | B1 |
| 6761714 | Abboud et al. | Jul 2004 | B2 |
| 6780181 | Kroll et al. | Aug 2004 | B2 |
| 6849073 | Hoey et al. | Feb 2005 | B2 |
| 6855143 | Davison et al. | Feb 2005 | B2 |
| 6887234 | Abboud et al. | May 2005 | B2 |
| 6911026 | Hall et al. | Jun 2005 | B1 |
| 6932814 | Wood | Aug 2005 | B2 |
| 6936024 | Houser | Aug 2005 | B1 |
| 6960209 | Clague et al. | Nov 2005 | B2 |
| 6971983 | Cancio | Dec 2005 | B1 |
| 6981972 | Farley et al. | Jan 2006 | B1 |
| 7059330 | Makower et al. | Jun 2006 | B1 |
| 7060063 | Marion et al. | Jun 2006 | B2 |
| 7094235 | Francischelli | Aug 2006 | B2 |
| 7155293 | Westlund et al. | Dec 2006 | B2 |
| 7179270 | Makower | Feb 2007 | B2 |
| 7189231 | Clague et al. | Mar 2007 | B2 |
| 7214234 | Rapacki et al. | May 2007 | B2 |
| 7231260 | Wallace et al. | Jun 2007 | B2 |
| 7250051 | Francischelli | Jul 2007 | B2 |
| 7288075 | Parihar et al. | Oct 2007 | B2 |
| 7303554 | Lalonde et al. | Dec 2007 | B2 |
| 7306598 | Truckai et al. | Dec 2007 | B2 |
| 7335198 | Eggers et al. | Feb 2008 | B2 |
| 7341063 | Garbibaldi et al. | Mar 2008 | B2 |
| 7367341 | Anderson et al. | May 2008 | B2 |
| 7374567 | Heuser | May 2008 | B2 |
| 7387636 | Cohn et al. | Jun 2008 | B2 |
| 7407506 | Makower | Aug 2008 | B2 |
| 7628768 | Faul et al. | Dec 2009 | B2 |
| 7702387 | Stevenson et al. | Apr 2010 | B2 |
| 7727268 | Cunniffe et al. | Jun 2010 | B2 |
| 7744596 | Young et al. | Jun 2010 | B2 |
| 7811281 | Rentrop | Oct 2010 | B1 |
| 7828814 | Brenneman et al. | Nov 2010 | B2 |
| 7846172 | Makower | Dec 2010 | B2 |
| 7849860 | Makower et al. | Dec 2010 | B2 |
| 7857809 | Drysen | Dec 2010 | B2 |
| 7881797 | Griffin et al. | Feb 2011 | B2 |
| 7955326 | Paul et al. | Jun 2011 | B2 |
| 7967769 | Faul et al. | Jun 2011 | B2 |
| 7967770 | Li et al. | Jun 2011 | B2 |
| 8010208 | Nimer et al. | Aug 2011 | B2 |
| 8048016 | Faul et al. | Nov 2011 | B2 |
| 8052680 | Hassett et al. | Nov 2011 | B2 |
| 8062321 | Heuser et al. | Nov 2011 | B2 |
| RE43007 | Lalonde et al. | Dec 2011 | E |
| 8075555 | Truckai et al. | Dec 2011 | B2 |
| 8088171 | Brenneman | Jan 2012 | B2 |
| 8100899 | Doty et al. | Jan 2012 | B2 |
| 8118809 | Paul et al. | Feb 2012 | B2 |
| 8135467 | Markowitz et al. | Mar 2012 | B2 |
| 8142454 | Harrison et al. | Mar 2012 | B2 |
| 8192425 | Mirza et al. | Jun 2012 | B2 |
| 8200466 | Spilker et al. | Jun 2012 | B2 |
| 8226592 | Brenneman et al. | Jul 2012 | B2 |
| 8231618 | Viswanathan et al. | Jul 2012 | B2 |
| 8236014 | Brenneman et al. | Aug 2012 | B2 |
| 8262649 | Francischelli | Sep 2012 | B2 |
| 8273095 | Brenneman et al. | Sep 2012 | B2 |
| 8328797 | Wilson et al. | Dec 2012 | B2 |
| 8333758 | Joye et al. | Dec 2012 | B2 |
| 8361061 | Esch et al. | Jan 2013 | B2 |
| 8366707 | Kassab et al. | Feb 2013 | B2 |
| 8382697 | Brenneman et al. | Feb 2013 | B2 |
| 8409196 | Durgin et al. | Apr 2013 | B2 |
| 8413664 | Appling | Apr 2013 | B2 |
| 8414572 | Davison et al. | Apr 2013 | B2 |
| 8419681 | Sell | Apr 2013 | B2 |
| 8439909 | Wang et al. | May 2013 | B2 |
| 8454587 | Lalonde et al. | Jun 2013 | B2 |
| 8475441 | Babkin et al. | Jul 2013 | B2 |
| 8486062 | Belhe et al. | Jul 2013 | B2 |
| 8486064 | Van Wyk et al. | Jul 2013 | B2 |
| 8551032 | Faul et al. | Oct 2013 | B2 |
| 8574185 | Faul et al. | Nov 2013 | B2 |
| 8585700 | Katou | Nov 2013 | B2 |
| 8608754 | Wensel et al. | Dec 2013 | B2 |
| 8641724 | Brenneman et al. | Feb 2014 | B2 |
| 8649879 | DiGiore et al. | Feb 2014 | B2 |
| 8676309 | Deem et al. | Mar 2014 | B2 |
| 8685014 | Babkin et al. | Apr 2014 | B2 |
| 8700179 | Pianca et al. | Apr 2014 | B2 |
| 8715281 | Barlow et al. | May 2014 | B2 |
| 8758334 | Coe et al. | Jun 2014 | B2 |
| 8771267 | Kunis et al. | Jul 2014 | B2 |
| 8784409 | Robilotto et al. | Jul 2014 | B2 |
| 8790341 | Pappone et al. | Jul 2014 | B2 |
| 8876699 | Sato et al. | Nov 2014 | B2 |
| 8876815 | Coe et al. | Nov 2014 | B2 |
| 8882765 | Kassab et al. | Nov 2014 | B2 |
| 8911435 | Katoh et al. | Dec 2014 | B2 |
| 8951251 | Willard | Feb 2015 | B2 |
| 9017323 | Miller et al. | Apr 2015 | B2 |
| 9039702 | Miller et al. | May 2015 | B2 |
| 9072880 | Phillips et al. | Jul 2015 | B2 |
| 9089316 | Baust et al. | Jul 2015 | B2 |
| 9108018 | Dickinson et al. | Aug 2015 | B2 |
| 9155827 | Franano | Oct 2015 | B2 |
| 9204916 | Lalonde | Dec 2015 | B2 |
| 9259340 | Heuser et al. | Feb 2016 | B2 |
| 9283034 | Katoh et al. | Mar 2016 | B2 |
| 9307992 | Wilson et al. | Apr 2016 | B2 |
| 9314329 | Dickinson et al. | Apr 2016 | B2 |
| 9326792 | Dickinson et al. | May 2016 | B2 |
| 9364280 | Zarins et al. | Jun 2016 | B2 |
| 9402560 | Organ et al. | Aug 2016 | B2 |
| 9414885 | Willard | Aug 2016 | B2 |
| 9439728 | Hull et al. | Sep 2016 | B2 |
| 9445868 | Hull et al. | Sep 2016 | B2 |
| 9452015 | Kellerman et al. | Sep 2016 | B2 |
| 9486276 | Rios et al. | Nov 2016 | B2 |
| 9623217 | Pillai | Apr 2017 | B2 |
| 9706998 | Dickinson et al. | Jul 2017 | B2 |
| 9782201 | Dickinson et al. | Oct 2017 | B2 |
| 9782533 | Brenneman et al. | Oct 2017 | B2 |
| 10045817 | Miller et al. | Aug 2018 | B2 |
| 10265206 | Heuser et al. | Apr 2019 | B2 |
| 10517637 | Dickinson et al. | Dec 2019 | B2 |
| 10543308 | Lenihan et al. | Jan 2020 | B2 |
| 10575974 | De Pablo Pena et al. | Mar 2020 | B2 |
| 10596356 | Lenihan et al. | Mar 2020 | B2 |
| 20010029384 | Nicholas et al. | Oct 2001 | A1 |
| 20020072739 | Lee et al. | Jun 2002 | A1 |
| 20020113678 | Creighton | Aug 2002 | A1 |
| 20020151945 | Gobin et al. | Oct 2002 | A1 |
| 20030009163 | Messing et al. | Jan 2003 | A1 |
| 20030220674 | Anderson et al. | Nov 2003 | A1 |
| 20040059211 | Patel et al. | Mar 2004 | A1 |
| 20040059280 | Makower et al. | Mar 2004 | A1 |
| 20040098095 | Burnside et al. | May 2004 | A1 |
| 20040167506 | Chen | Aug 2004 | A1 |
| 20040215220 | Dolan et al. | Oct 2004 | A1 |
| 20040236360 | Cohn et al. | Nov 2004 | A1 |
| 20050033401 | Cunniffe et al. | Feb 2005 | A1 |
| 20050065509 | Coldwell et al. | Mar 2005 | A1 |
| 20050245925 | Iki et al. | Nov 2005 | A1 |
| 20050251120 | Anderson et al. | Nov 2005 | A1 |
| 20060079897 | Harrison et al. | Apr 2006 | A1 |
| 20060111704 | Brenneman et al. | May 2006 | A1 |
| 20070173878 | Heuser | Jul 2007 | A1 |
| 20070185567 | Heuser et al. | Aug 2007 | A1 |
| 20070203515 | Heuser et al. | Aug 2007 | A1 |
| 20070203572 | Heuser et al. | Aug 2007 | A1 |
| 20070293856 | Paul et al. | Dec 2007 | A1 |
| 20080021532 | Kveen et al. | Jan 2008 | A1 |
| 20080051626 | Sato et al. | Feb 2008 | A1 |
| 20080065019 | Heuser et al. | Mar 2008 | A1 |
| 20080091192 | Paul et al. | Apr 2008 | A1 |
| 20080119879 | Brenneman et al. | May 2008 | A1 |
| 20080140061 | Toubia et al. | Jun 2008 | A1 |
| 20080161901 | Heuser et al. | Jul 2008 | A1 |
| 20080171944 | Brenneman | Jul 2008 | A1 |
| 20080183164 | Elkins et al. | Jul 2008 | A1 |
| 20080188848 | Deutmeyer et al. | Aug 2008 | A1 |
| 20080275442 | Paul et al. | Nov 2008 | A1 |
| 20080312577 | Drasler et al. | Dec 2008 | A1 |
| 20090036872 | Fitzgerald et al. | Feb 2009 | A1 |
| 20090076324 | Takayama et al. | Mar 2009 | A1 |
| 20090093791 | Heuser | Apr 2009 | A1 |
| 20090112119 | Kim | Apr 2009 | A1 |
| 20090118722 | Ebbers et al. | May 2009 | A1 |
| 20090124847 | Doty et al. | May 2009 | A1 |
| 20090157014 | Osborne | Jun 2009 | A1 |
| 20090198232 | Young et al. | Aug 2009 | A1 |
| 20090248148 | Shaolian et al. | Oct 2009 | A1 |
| 20090275876 | Brenneman et al. | Nov 2009 | A1 |
| 20090281379 | Binmoeller et al. | Nov 2009 | A1 |
| 20090318849 | Hobbs et al. | Dec 2009 | A1 |
| 20100004623 | Hamilton, Jr. et al. | Jan 2010 | A1 |
| 20100010488 | Kassab et al. | Jan 2010 | A1 |
| 20100082058 | Kassab | Apr 2010 | A1 |
| 20100130835 | Brenneman et al. | May 2010 | A1 |
| 20100198206 | Levin | Aug 2010 | A1 |
| 20100204691 | Bencini | Aug 2010 | A1 |
| 20100222664 | Lemon et al. | Sep 2010 | A1 |
| 20100256616 | Katoh et al. | Oct 2010 | A1 |
| 20100280316 | Dietz et al. | Nov 2010 | A1 |
| 20100280514 | Zerfas et al. | Nov 2010 | A1 |
| 20100286705 | Vassiliades, Jr. | Nov 2010 | A1 |
| 20100292685 | Katoh et al. | Nov 2010 | A1 |
| 20100298645 | Deutch | Nov 2010 | A1 |
| 20100318180 | Porter | Dec 2010 | A1 |
| 20110015657 | Brenneman et al. | Jan 2011 | A1 |
| 20110112427 | Phillips et al. | May 2011 | A1 |
| 20110118735 | Abou-Marie et al. | May 2011 | A1 |
| 20110201990 | Franano | Aug 2011 | A1 |
| 20110213309 | Young et al. | Sep 2011 | A1 |
| 20110218476 | Kraemer et al. | Sep 2011 | A1 |
| 20110270149 | Faul et al. | Nov 2011 | A1 |
| 20110288392 | de la Rama et al. | Nov 2011 | A1 |
| 20110288544 | Verin et al. | Nov 2011 | A1 |
| 20110306959 | Kellerman et al. | Dec 2011 | A1 |
| 20110306993 | Hull et al. | Dec 2011 | A1 |
| 20110319976 | Iyer et al. | Dec 2011 | A1 |
| 20120010556 | Faul et al. | Jan 2012 | A1 |
| 20120022518 | Levinson | Jan 2012 | A1 |
| 20120035539 | Tegg | Feb 2012 | A1 |
| 20120046678 | LeMaitre et al. | Feb 2012 | A1 |
| 20120059398 | Pate et al. | Mar 2012 | A1 |
| 20120065652 | Cully et al. | Mar 2012 | A1 |
| 20120078342 | Vollkron et al. | Mar 2012 | A1 |
| 20120089123 | Organ et al. | Apr 2012 | A1 |
| 20120101423 | Brenneman | Apr 2012 | A1 |
| 20120116354 | Heuser | May 2012 | A1 |
| 20120157992 | Smith et al. | Jun 2012 | A1 |
| 20120209377 | Machold et al. | Aug 2012 | A1 |
| 20120215088 | Wang et al. | Aug 2012 | A1 |
| 20120239021 | Doty et al. | Sep 2012 | A1 |
| 20120277736 | Francischelli | Nov 2012 | A1 |
| 20120281330 | Abbott et al. | Nov 2012 | A1 |
| 20120289953 | Berzak et al. | Nov 2012 | A1 |
| 20120296262 | Ogata et al. | Nov 2012 | A1 |
| 20120302935 | Miller | Nov 2012 | A1 |
| 20130041306 | Faul et al. | Feb 2013 | A1 |
| 20130056876 | Harvey et al. | Mar 2013 | A1 |
| 20130110105 | Vankov | May 2013 | A1 |
| 20130172881 | Hill et al. | Jul 2013 | A1 |
| 20130190744 | Avram et al. | Jul 2013 | A1 |
| 20130190754 | Paul et al. | Jul 2013 | A1 |
| 20130216351 | Griffin | Aug 2013 | A1 |
| 20130226170 | Seddon et al. | Aug 2013 | A1 |
| 20130261368 | Schwartz | Oct 2013 | A1 |
| 20130282000 | Parsonage | Oct 2013 | A1 |
| 20140031674 | Newman et al. | Jan 2014 | A1 |
| 20140094791 | Hull et al. | Apr 2014 | A1 |
| 20140100557 | Bohner et al. | Apr 2014 | A1 |
| 20140100562 | Sutermeister et al. | Apr 2014 | A1 |
| 20140107642 | Rios | Apr 2014 | A1 |
| 20140166098 | Kian et al. | Jun 2014 | A1 |
| 20140188028 | Brenneman et al. | Jul 2014 | A1 |
| 20140276335 | Pate | Sep 2014 | A1 |
| 20150005759 | Welches et al. | Jan 2015 | A1 |
| 20150011909 | Holmin et al. | Jan 2015 | A1 |
| 20150018810 | Baust et al. | Jan 2015 | A1 |
| 20150057654 | Leung et al. | Feb 2015 | A1 |
| 20150057687 | Gittard et al. | Feb 2015 | A1 |
| 20150080886 | Miller et al. | Mar 2015 | A1 |
| 20150094645 | Omar-Pasha | Apr 2015 | A1 |
| 20150112195 | Berger et al. | Apr 2015 | A1 |
| 20150126965 | Liungman | May 2015 | A1 |
| 20150134055 | Spence et al. | May 2015 | A1 |
| 20150141836 | Naumann et al. | May 2015 | A1 |
| 20150164573 | Delaney | Jun 2015 | A1 |
| 20150196356 | Kauphusman et al. | Jul 2015 | A1 |
| 20150196360 | Grantham et al. | Jul 2015 | A1 |
| 20150201962 | Kellerman et al. | Jul 2015 | A1 |
| 20150258308 | Pate | Sep 2015 | A1 |
| 20150297259 | Matsubara et al. | Oct 2015 | A1 |
| 20150313668 | Miller et al. | Nov 2015 | A1 |
| 20150320472 | Ghaffari et al. | Nov 2015 | A1 |
| 20160022345 | Baust et al. | Jan 2016 | A1 |
| 20160058452 | Brenneman et al. | Mar 2016 | A1 |
| 20160058956 | Cohn et al. | Mar 2016 | A1 |
| 20160067449 | Misener et al. | Mar 2016 | A1 |
| 20160082234 | Schwartz et al. | Mar 2016 | A1 |
| 20160128855 | Heuser et al. | May 2016 | A1 |
| 20160135881 | Katoh et al. | May 2016 | A1 |
| 20160184011 | Krishnan | Jun 2016 | A1 |
| 20160206317 | Dickinson | Jul 2016 | A1 |
| 20170119464 | Rios et al. | May 2017 | A1 |
| 20170172679 | Doty et al. | Jun 2017 | A1 |
| 20170202603 | Cohn et al. | Jul 2017 | A1 |
| 20170202616 | Pate et al. | Jul 2017 | A1 |
| 20180000512 | Dickinson et al. | Jan 2018 | A1 |
| 20180083228 | Yang et al. | Mar 2018 | A1 |
| 20180116522 | Brenneman et al. | May 2018 | A1 |
| 20180206845 | Brenneman et al. | Jul 2018 | A1 |
| 20180344396 | Miller et al. | Dec 2018 | A1 |
| 20200061338 | Pate | Feb 2020 | A1 |
| Number | Date | Country |
|---|---|---|
| 2883209 | Apr 2014 | CA |
| 1730123 | Feb 2006 | CN |
| 101730557 | Jun 2010 | CN |
| 0923912 | Jun 1999 | EP |
| 3127126 | Nov 2006 | JP |
| 2168951 | Jun 2001 | RU |
| 9956640 | Nov 1999 | WO |
| 2006105008 | Oct 2006 | WO |
| 2008010039 | Jan 2008 | WO |
| 2009005644 | Jan 2009 | WO |
| 2011100625 | Aug 2011 | WO |
| 2013112584 | Aug 2013 | WO |
| 2014052919 | Apr 2014 | WO |
| 2015061614 | Apr 2015 | WO |
| 2015085119 | Jun 2015 | WO |
| 2015108984 | Jul 2015 | WO |
| 2016033380 | Mar 2016 | WO |
| 2017124059 | Jul 2017 | WO |
| 2017124060 | Jul 2017 | WO |
| 2018057095 | Mar 2018 | WO |
| Entry |
|---|
| Extended European Search Report pertaining to EP Patent Application No. 17853586.0, dated Apr. 29, 2020. |
| Extended European Search Report for EP Application No. 17739123.2. |
| Maybury et al., “The Effect of Roll Angle on the Performance of Halbach Arrays,” University of California—San Diego, Center for Magnetic Recording Research (2008), 19 pgs. |
| Choi, et al., Design of a Halbach Magnet Array Based on Optimization Techniques; IEEE Transactions on Magnetics, vol. 44, No. 10, Oct. 2008, pp. 2361-2366. (Year: 2008). |
| “Banasik et al. (2011).”“A rare variant route of the ulnar artery does not contraindicate the creation of a fistula in the wrist of a diabetic patient with end-stage renal disease,”“Postepy Hig Med Dosw. 65:654-657.” |
| Bharat et al. (2012) “A novel technique of vascular anastomosis to prevent juxta-anastomotic stenosis following arteriovenous fistula creation,” J. Vascular Surgery 55(1):274-280. |
| Bode et al. (2011 ). “Clinical study protocol for the arch project Computational modeling for improvement of outcome after vascular access creation,” J. Vase. Access 12(4):369-376. |
| Hakim et al., “Ulnar artery-based free forearm flap: Review of Specific anatomic features in 322 cases and related literature,” Heand & Neck, Dec. 2013 (published online:2014), Wiley Online Library. |
| Davidson, I. et al. (2008). “Duplex Ultrasound Evaluation for Dialysis Access Selection and Maintenance: A Practical Guide,” The Journal of Vascular Access 9(1 ): 1-9. |
| Gracz, et al. (1977). “Proximal forearm fistula for maintenance hemodialysis,” Kidney International 11 :71-75. |
| Jennings, WC. et al. (2011). “Primary arteriovenous fistula inflow proximalization for patients at high risk for dialysis access-associated ischemic steal syndrome,” J Vase. Surgery 54(2):554-558. |
| Kinnaert, et al. (1971). “Ulnar Arteriovenous Fistula for Maintenance Haemodial Ysis,” British J. Surgery 58(9):641-643. |
| Morale et al. (2011). “Venae comitantes as a potential vascular resource to create native arteriovenous fistulae,” J. Vase. Access 12(3):211-214. |
| Shenoy, S. (2009). “Surgical anatomy of upper arm: what is needed for AVF planning,” The Journal of Vascular Access 10:223-232. |
| Vachharajani, T. (2010). “Atlas of Dialysis Vascular Access,” Wake Forest University School of Medicine, 77 total pages. |
| Whittaker et al. (2011). “Prevention better than cure. Avoiding steal syndrome with proximal radial or ulnar arteriovenous fistulae” J. Vase. Access 12(4):318-320. |
| Office Action dated Jun. 4, 2021, pertaining to Japanese Patent Application No. 2019-516190. |
| Office Action pertaining to corresponding Japanese Patent Application No. 2018-536423, dated Feb. 12, 2021. |
| Number | Date | Country | |
|---|---|---|---|
| 20190274855 A1 | Sep 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| 62399465 | Sep 2016 | US |